Skip to main content

Table 1 Molecular and clinical characteristics of patients with essential thrombocythemia (ET)

From: A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients

Variables CALR mutation (n = 22) JAK2 V617F mutation (n = 28) Triple Negative (n = 14) p-value
Males (%) 15 (68.2) 12 (42.9) 6 (42.9) 0.395
Age,
Median (Range)
35 (28–73) 57.5 (34.0–85.0) 35 (18–75) 0.001**
Risk Group:
 Low (%) 15 14 2 0.043*
 High (%) 7 14 12  
Haemoglobin (g/dL),
Median (Range)
10.2 (9.2–11.1) 12.3 (10.5–15.1) 12.8 (11.7–16.8) 0.641
TLC ×109/L,
Median (Range)
9.3 (5.11–16.7) 9.5 (4.7–147) 11.2 (2.3147) 0.061
Platelet ×109/L,
Median (Range)
1003.0 (462–2305) 928.5 (92–1883) 1064.5 (382–1841) 0.373
Reticulin Fibrosis
MF 0 12 (54.5) 20 (71.4) 10 (71.4)  
MF 1 7 (318) 8 (28.6) 4 (28.6) 0.052
MF 2 3 (13.6) 0 0  
Constitutional symptoms (%) 13 (59.1) 13 (46.4) 4 (28.6)  
Thromboembolic events (%) 3 (13.6) 4 (14.3) 2(14.3) 0.033*
  1. **highly significant, *significant